Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Current Leases (2021 - 2025)

Historic Current Leases for Avidity Biosciences (RNA) over the last 5 years, with Q3 2025 value amounting to $4.0 million.

  • Avidity Biosciences' Current Leases rose 428.5% to $4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year increase of 428.5%. This contributed to the annual value of $3.8 million for FY2024, which is 563.34% up from last year.
  • As of Q3 2025, Avidity Biosciences' Current Leases stood at $4.0 million, which was up 428.5% from $3.9 million recorded in Q2 2025.
  • Over the past 5 years, Avidity Biosciences' Current Leases peaked at $4.0 million during Q3 2025, and registered a low of $1.8 million during Q4 2021.
  • Moreover, its 5-year median value for Current Leases was $3.6 million (2023), whereas its average is $3.4 million.
  • Per our database at Business Quant, Avidity Biosciences' Current Leases soared by 7552.29% in 2022 and then skyrocketed by 270.53% in 2023.
  • Quarter analysis of 5 years shows Avidity Biosciences' Current Leases stood at $1.8 million in 2021, then skyrocketed by 75.52% to $3.1 million in 2022, then rose by 17.2% to $3.6 million in 2023, then rose by 5.63% to $3.8 million in 2024, then increased by 3.2% to $4.0 million in 2025.
  • Its Current Leases stands at $4.0 million for Q3 2025, versus $3.9 million for Q2 2025 and $3.9 million for Q1 2025.